Clearside Says Uveitis Indication For Xipere Would Keep Company Afloat
Following failure and discontinuation of Phase III studies in retinal vein occlusion, company says it will have enough cash to get through 2020.
Following failure and discontinuation of Phase III studies in retinal vein occlusion, company says it will have enough cash to get through 2020.